RA Capital Management - Q1 2022 holdings

$4.58 Billion is the total value of RA Capital Management's 96 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 61.1% .

 Value Shares↓ Weighting
TVTX SellTRAVERE THERAPEUTICS INC$126,864,000
-27.2%
4,922,941
-12.3%
2.77%
-9.9%
NVAX SellNOVAVAX INC$51,024,000
-83.0%
692,794
-67.0%
1.11%
-79.0%
SCPH SellSCPHARMACEUTICALS INC$15,101,000
+11.8%
2,658,583
-1.2%
0.33%
+38.2%
LRMR SellLARIMAR THERAPEUTICS INC$5,192,000
-63.9%
1,281,860
-4.0%
0.11%
-55.5%
SellTSCAN THERAPEUTICS INC$2,861,000
-49.4%
1,021,764
-18.6%
0.06%
-38.0%
OLMA SellOLEMA PHARMACEUTICALS INC$2,149,000
-89.3%
504,505
-76.5%
0.05%
-86.8%
CMPX SellCOMPASS THERAPEUTICS INC$730,000
-87.5%
532,958
-71.2%
0.02%
-84.5%
SYRS ExitSYROS PHARMACEUTICALS INC$0-900,000
-100.0%
-0.05%
COGT ExitCOGENT BIOSCIENCES INC$0-1,025,641
-100.0%
-0.16%
IKNA ExitIKENA ONCOLOGY INC$0-750,000
-100.0%
-0.17%
SBTX ExitSILVERBACK THERAPEUTICS INC$0-1,742,186
-100.0%
-0.20%
BOLT ExitBOLT BIOTHERAPEUTICS INC$0-2,378,325
-100.0%
-0.20%
NAUT ExitNAUTILUS$0-2,436,430
-100.0%
-0.22%
ExitADAGIO THERAPEUTICS INC$0-4,995,807
-100.0%
-0.64%
TGTX ExitTG THERAPEUTICS INC$0-2,210,145
-100.0%
-0.74%
CCCC ExitC4 THERAPEUTICS INC$0-1,377,569
-100.0%
-0.78%
ZGNX ExitZOGENIX INC$0-3,333,700
-100.0%
-0.96%
PHAT ExitPHATHOM PHARMACEUTICALS INC$0-3,115,008
-100.0%
-1.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q1 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ARS Pharmaceuticals, Inc.September 25, 20239,459,6789.9%
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
32024-03-27
42024-03-27
32024-03-25
42024-03-25
SC 13G2024-03-25
SC 13G2024-03-25
SC 13D/A2024-03-18
SC 13D/A2024-03-11
42024-03-06
42024-03-06

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings